023910 — Dai Han Pharm Co Balance Sheet
0.000.00%
- KR₩158bn
- KR₩81bn
- KR₩204bn
- 87
- 90
- 81
- 98
Annual balance sheet for Dai Han Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 67,600 | 96,415 | 97,607 | 104,359 | 77,237 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 30,188 | 30,384 | 33,264 | 31,878 | 33,309 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 121,684 | 147,539 | 155,886 | 159,905 | 137,366 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 113,396 | 113,831 | 113,236 | 125,853 | 134,441 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 253,090 | 272,542 | 276,980 | 294,252 | 324,411 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 39,224 | 46,119 | 42,686 | 41,300 | 42,644 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 71,166 | 69,734 | 51,582 | 46,278 | 48,418 |
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 181,923 | 202,808 | 225,398 | 247,974 | 275,994 |
Total Liabilities & Shareholders' Equity | 253,090 | 272,542 | 276,980 | 294,252 | 324,411 |
Total Common Shares Outstanding |